Vascular malformations are part of overgrowth syndromes characterized by somatic mosaic mutations or rarely by germline mutations. Due to their similarities and diversity, clinicopathological classification can be challenging. A comprehensive targeted Next Generation Sequencing screen using Unique Molecular Identifiers with a technical sensitivity of 1% mutant alleles was performed for frequently mutated positions in ≥21 genes on 319 formalin-fixed paraffin-embedded samples. In 132 out of 319 cases pathogenic mosaic mutations were detected affecting genes previously linked to vascular malformations e.g.
(activating mutations in GNAQ) 13 and Maffucci syndrome (transforming mutations in IDH1 and IDH2).
14 Other somatically mutated genes comprise TEK/TIE2 (activating mutations, mainly described in venous malformations), 8 
KRAS, NRAS,
and HRAS (activating mutations, mainly described in arteriovenous malformations), 15, 16 GLMN (disrupting mutations in glomuvenous malformations) 17 and GNA11 and GNA14 (activating mutations in vascular lesions described as vascular tumors including congenital tufted angiomas and kaposiform hemangioendotheliomas). 18 Germline RASA1-mutations have been described in patients with
Parkes Weber Syndrome and Capillary Malformation-ArterioVenous
Malformations (CM-AVM). 19, 20 The PTEN Hamartoma Tumor Syndrome includes Bannayan-Riley-Ruvalcaba syndrome (BRRS) and
Cowden syndrome (CS) harboring disrupting (germline) mutations in PTEN. 21, 22 Hereditary hemorrhagic telangiectasia bears disrupting germline mutations in ENG and ACVRL1. 19 Other known syndromes and disorders that may include vascular anomalies are BeckwithWiedemann syndrome, Noonan syndrome, Turner's syndrome, Klinefelters syndrome, and Neurofibromatosis. 1 To gain better insight into the biology of vascular malformations and overgrowth syndromes, their mutational spectrum and potential therapeutic options, we performed Next Generation Sequencing (NGS) analysis with a sensitivity of 1% variant allele frequency to allow detection of low abundant mosaic mutations in formalin-fixed paraffin-embedded (FFPE) tissue from 319 clinical cases.
| MATERIALS AND METHODS
The 319 included cases are combined from a prospective and a retro- All samples were fixed in 4% buffered formalin, routinely processed and embedded in paraffin. Four micrometer thick sections were stained with hematoxylin and eosin.
DNA isolation and library preparation were performed as previously described. 23, 24 Briefly, gDNA was isolated from FFPE tissue sections (generally 3 × 20 μm) using 5% Chelex-100 and 400 μg proteinase K and DNA concentrations were measured using the Qubit Broad Range kit (Q32853; ThermoFisher). When available, 150 ng of gDNA representing an equivalent of~25 000 cells was used per library preparation. In the remaining cases, the available amount of DNA was used with a minimum of 5 ng representing
gDNA from approximately 800 cells.
Libraries for sequencing on the NextSeq 500 (Illumina) were generated using Single Molecule Molecular Inversion Probes (smMIPs). 24 This method uses unique molecule identifiers (UMI's) to allow consensus-based error correction and the deduction of the actual number of sequenced gDNA molecules. Genetic data from our entire prospective cohort were correlated with clinical and histopathological features.
3 | RESULTS
| Molecular results
The identified pathogenic and likely pathogenic variants are listed in Table 1 and Supporting Information Table S2 (all PIK3CA mutated cases).
3.1.1 | The spectrum of gain of function (hotspot mutations)
Prospective cohort
Nineteen out of 217 prospective cases obtained insufficient coverage.
Of the remaining 198 cases, 77 had mutations: 53 PIK3CA, 6 GNAQ, 6 KRAS, 3 IDH1, 3 GNA11, 1 NRAS, and 1 AKT1 pathogenic mutations.
Four cases harbored two mutations: PIK3CA and GNA11 (n = 2), PIK3CA and GNAQ, and PIK3CA (n = 1) and IDH1 (n = 1).
Retrospective cohort
In the retrospective cohort (n = 102), 14 Figure 1 .
Overall, we discovered gain of function (hotspot) mutations in a total of 122 cases (43%), with allele frequencies ranging from 2% to 24%. The mutant allele frequencies of 72% of cases (n = 88) were below the presumed detection limit of 10% for Sanger and first generation NGS approaches ( Figure 2 ). Six of all mutated cases (5%) harbored a combination of known pathogenic mutations in PIK3CA with mutations in GNA11, GNAQ, or IDH1 with comparable mutant allele frequencies ( Figure 3 ).
| Loss of function mutations
In addition to the mutations investigated earlier, the retrospective cohort (n = 88/102) was analyzed for loss of function mutations in PTEN, RASA1, ACVRL1, ENG, and relevant exons of GLMN. We identified pathogenic loss of function mutations in PTEN (9 cases) and RASA1 (1 case) (Figure 4 ), mutually exclusive with the earlier described hotspot mutations. Six cases had mutant allele frequencies >40%.
Because the tissue selection for DNA isolation in these cases was identical to the other cases in the cohort and mutant allele frequencies >40% were not identified for any of the other genes, this was Tables S3 and S4 ). Also unique coverage of RASA1 was insufficient to exclude the presence of mutations in other cases.
| Clinical data
The PIK3CA mutated lesions were mainly low flow (lymphatic and/or venous) malformations, but comprised heterogeneous clinical aspects as reported in the literature. 2, 25, 26 Three patients had clinical characteristics of Klippel Trenaunay syndrome ( Table 1) .
The clinical data of the 42 cases harboring hotspot mutations other than PIK3CA are shown in Table 1 Of the cases with double mutations, the first case with a PIK3CA
and GNAQ mutation was an intraosseous/dural vascular lesion and the second case was a small relatively well-circumscribed high flow skin lesion. One of the two cases with both a PIK3CA and a GNA11 mutation concerned a low flow lesion in the nose with bleeding. The clinical information of the other case was unknown. Finally, the two cases with both a PIK3CA and an IDH1 mutation were both clinically atypical vascular skin lesions localized on the site of the scapula and the leg, respectively. Overall, these 6 cases had no special clinical signs indicating their double mutations.
Reasons for obtaining tissue were also diverse. In 13 patients a diagnostic biopsy was taken for genetic analysis. In 17 cases tissue was surgically removed for various reasons: for correction (n = 7), to reduce pain (n = 3), and because of progression (n = 5) involving one case with paraplegia due to an epidural mass and twice an amputation of a lower leg and a finger, respectively. Other reasons were treatment of varicosity, phlebitis, and a debulking resection because of a massive lesion in the upper lip. Only sparse clinical information was available for 12 patients.
| Correlation of histology and molecular findings
The PIK3CA mutated cases depicted variable histology ranging from simple to combined capillary, lymphatic, and venous malformations and AVMs. All 11 cases with activating mutations in TEK were noncircumscribed mostly combined venous, capillary, and/or lymphatic lesions without an arterial component. Eight of the eleven cases with RAS (9 KRAS, 1 NRAS, and 1 RASA1) mutations were well-circumscribed capillary and/or venous/cavernous malformations ( Figure 5 ). The remaining 2 cases were noncircumscribed AVMs ( Figure 6 ). Two of three cases with an IDH1 mutation, were typical spindle cell hemangiomas (SCH) and the third sample showed an intramuscular veno-capillary malformation. All 4 GNA11 mutated cases had mutation were SCHs. The other 4 cases with a PIK3CA mutation combined with either a GNA11 (n = 2) or GNAQ (n = 2) mutation were all veno-capillary malformations. Histology of the RASA1 and PTEN mutated cases could not be determined due to anonymization.
In the prospective cohort (n = 198/217), mutations and the percentages of mutated cells within the histologically determined groups are shown in Supporting Information Table S5 .
The spectrum of mutations per group was, based on clinical and histological features, relatively heterogeneous. The capillary malformations, for example, showed 3 GNAQ and 3 KRAS mutations, 1 NRAS and 1 PIK3CA mutation, and also a combined PIK3CA with GNA11 mutation. In AVMs (4 out of 17) and LMs (8 out of 14), without exception however, PIK3CA mutations were identified.
| DISCUSSION
Vascular malformations belonging to the spectrum of overgrowth syndromes are, in most cases, genetically characterized by somatic mosaic pathogenic hotspot mutations or, more rarely, by germline mutations. 1 We analyzed frequently mutated positions in more than 20 genes in clinically/radiologically and/or histopathologically diagnosed vascular malformations/overgrowth syndromes to gain more insight into their molecular biology linked to clinicopathological characteristics. Clinically, all cases had a venous phenotype including 1 case with a BRBN syndrome. Both TEK mutations found in the BRBN case were present in cis. As all mutated reads contained both mutations, the same variant allele frequency was suggested. 34 In contrast to the 
| Technical challenges for molecular diagnostics

| RAS-RAF-MEK-ERK signaling pathway
RAS signaling can be stimulated by both activating (somatic) mutations in KRAS, HRAS, NRAS as well as inactivating (germline) mutations in RASA1, which is a RAS-GAP (Guanine Activating Protein) and negative regulator of the RAS-RAF-MEK-ERK signaling pathway. Subsequently, diverse cellular signaling networks including the mTOR and ERK pathways are activated. 35 Histologically, in contrast with the heterogeneity seen for the other mutations, 8 out of 11 RAS mutated vascular malformations were well-circumscribed (capillary and/or venous), while lesions with other mutations were almost all noncircumscribed.
GNAQ is a gene encoding guanine nucleotide binding protein G(q) alpha, a subunit within a complex that hydrolyses the intracellular messenger GTP to GDP. 36 GNA11 and GNA14 are analogous binding proteins with nearly the same protein sequence as GNAQ. 18, 36 When mutated, these genes induce changes in cellular morphology and cell growth by upregulation of mainly the RAS-RAF-MEK-ERK pathway. 18 Combining the two cohorts, we detected 9 KRAS, 1 NRAS, 7 GNAQ, and 4 GNA11 hotspot mutations; GNAQ and GNA11 were in 2 cases each combined with a PIK3CA mutation. These, and one inactivating mutation in RASA1, suggest a more significant role (about 8% of all the included cases) of the RAS-RAF-MEK-ERK pathway in vascular malformations than may be expected from the literature.
15,16
We did not detect GNA14 mutations. This is in accordance with the literature reporting that such mutations are restricted to tufted hemangioma and kaposiform hemangioendothelioma, which were not included in our cohorts. Five cases showed an IDH1 mutation, in two cases in combination with a PIK3CA mutation (one of these cases was included in a previously published cohort 37 ). Isocitrate dehydrogenases (IDH) are metabolic enzymes which, as a result of a somatic mutation (in both IDH1 and IDH2), mostly inhibit the catalyzation of isocitrate to α-ketoglutarate 
| Combined mutations
In 6 cases we identified a combination of an activating mutation in PIK3CA with an additional pathogenic mutation in GNAQ, GNA11, or IDH1. As these cases had a heterogeneous/combined phenotype without specific clinical symptoms, no conclusion can be drawn regarding the significance of the dominant mutation. We also identified 1 case with a potential germline RASA1 mutation. Because data from our retrospective cohort were analyzed anon- Complete analyses of all coding and splice site sequences is required to identify all disrupting mutations, in contrast to the aforementioned "hotspot" analyses; this is challenging when using relatively poor quality gDNA obtained from FFPE tissue. Due to limitations in horizontal and vertical coverage for ACVRL1, ENG, and GLMN, but also PTEN and RASA1, pathogenic disruptions in these genes may have been remained undetected.
| Therapeutic opportunities for vascular malformations
There is increasing evidence 28, 40 that sirolimus, an mTOR inhibitor, can be used to treat a subset of the vascular malformations with a more favorable balance between effect and side effects than conventional treatments like surgery, embolization, or laser therapy. 41 The precise mechanism behind this treatment is still unknown, but at least 107 of 286 cases in our series harbored mutations predicted to activate mTOR signaling. These mTOR activating cases are not limited to PIK3CA, so a more comprehensive analysis including additional genes involved in this pathway could increase the diagnostic and therapeutic yield (in our set-up by~25%). Similarly, MEK inhibitors seem to be a promising therapeutic agent for lesions harboring mutations involved in the RAS-RAF-MEK-ERK pathway 16 ; such mutations were found in 25 of our cases. 
